TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multi-center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (AHUS)
Brief Summary: The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS).


Options:
A: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): Eculizumab
B: Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eculizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albumin (Human) 25%, United States Pharmacopeia (USP) | Intervention Type: DRUG; Name: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Albumin (Human) 25%, United States Pharmacopeia (USP); Assigned to Arm(s): Group 2
D: Arm Label: eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): eculizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma
Brief Summary: The objective of this clinical study is to examine the safety and effectiveness of intravenous MN-221 compared to placebo when administered as an adjunct to standard therapy in subjects experiencing an acute exacerbation of asthma.


Options:
A: Arm Label: heliox; Type: EXPERIMENTAL; Interventions: Other: HELIOX | Arm Label: heliox+posture; Type: EXPERIMENTAL; Interventions: Other: HELIOX+POSTURE | Arm Label: oxygen+posture; Type: EXPERIMENTAL; Interventions: Other: OXYGEN + POSTURE | Arm Label: oxygen; Type: ACTIVE_COMPARATOR; Interventions: Other: OXYGEN | Intervention Type: OTHER; Name: HELIOX; Assigned to Arm(s): heliox | Intervention Type: OTHER; Name: OXYGEN; Assigned to Arm(s): oxygen | Intervention Type: OTHER; Name: HELIOX+POSTURE; Assigned to Arm(s): heliox+posture | Intervention Type: OTHER; Name: OXYGEN + POSTURE; Assigned to Arm(s): oxygen+posture
B: Arm Label: EzPAP; Type: EXPERIMENTAL; Interventions: Drug: EzPAP | Arm Label: Standard care; Type: SHAM_COMPARATOR; Interventions: Other: Standard Care | Intervention Type: DRUG; Name: EzPAP; Assigned to Arm(s): EzPAP | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard care
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MN-221 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: MN-221; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.
Brief Summary: A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.


Options:
A: Arm Label: Lira 0.6 + Met; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo, Drug: metformin | Arm Label: Lira 1.2 + Met; Type: EXPERIMENTAL; Interventions: Drug: placebo, Drug: liraglutide, Drug: metformin | Arm Label: Lira 1.8 + Met; Type: EXPERIMENTAL; Interventions: Drug: placebo, Drug: liraglutide, Drug: metformin | Arm Label: Glim + Met; Type: EXPERIMENTAL; Interventions: Drug: glimepiride, Drug: metformin, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 0.6 + Met | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 + Met | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 + Met | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Glim + Met | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Glim + Met, Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glim + Met
B: Arm Label: Omarigliptin; Type: EXPERIMENTAL; Interventions: Drug: Omarigliptin, Drug: Glimepiride Placebo, Drug: Metformin, Drug: Insulin Glargine | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo to Omarigliptin, Drug: Glimepiride, Drug: Metformin, Drug: Insulin Glargine | Intervention Type: DRUG; Name: Omarigliptin; Assigned to Arm(s): Omarigliptin | Intervention Type: DRUG; Name: Placebo to Omarigliptin; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Glimepiride Placebo; Assigned to Arm(s): Omarigliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glimepiride, Omarigliptin | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Glimepiride, Omarigliptin
C: Arm Label: albiglutide weekly injection; Type: EXPERIMENTAL; Interventions: Biological: albiglutide | Arm Label: insulin glargine; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine | Intervention Type: BIOLOGICAL; Name: albiglutide; Assigned to Arm(s): albiglutide weekly injection | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): insulin glargine
D: Arm Label: Pioglitazone QD; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Glyburide QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glyburide | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone QD | Intervention Type: DRUG; Name: Glyburide; Assigned to Arm(s): Glyburide QD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Acupuncture for Residual Insomnia Associated With Major Depressive Disorder
Brief Summary: The purpose of this study is to evaluate the clinical effectiveness of acupuncture treatment on residual insomnia in major depressive patients.


Options:
A: Arm Label: Traditional Acupuncture; Type: EXPERIMENTAL; Interventions: Other: Acupuncture | Arm Label: Minimal Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Other: Acupuncture | Arm Label: Placebo Acupuncture; Type: PLACEBO_COMPARATOR; Interventions: Other: Acupuncture | Intervention Type: OTHER; Name: Acupuncture; Assigned to Arm(s): Minimal Acupuncture, Placebo Acupuncture, Traditional Acupuncture
B: Arm Label: DCEAS; Type: EXPERIMENTAL; Interventions: Procedure: DCEAS (Hwato®/ Dongbang®), Procedure: Body electro-acupuncture (Hwato®/ Dongbang®), Drug: Fluoxetine | Arm Label: n-CEA; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Body electro-acupuncture (Hwato®/ Dongbang®), Procedure: n-CEA (Strietberger®), Drug: Fluoxetine | Intervention Type: PROCEDURE; Name: DCEAS (Hwato®/ Dongbang®); Assigned to Arm(s): DCEAS | Intervention Type: PROCEDURE; Name: Body electro-acupuncture (Hwato®/ Dongbang®); Assigned to Arm(s): DCEAS, n-CEA | Intervention Type: PROCEDURE; Name: n-CEA (Strietberger®); Assigned to Arm(s): n-CEA | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): DCEAS, n-CEA
C: Arm Label: Traditional Acupuncture; Type: EXPERIMENTAL; Interventions: Other: Acupuncture | Arm Label: Minimal Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Other: Acupuncture | Arm Label: Placebo Acupuncture; Type: PLACEBO_COMPARATOR; Interventions: Other: Acupuncture | Intervention Type: OTHER; Name: Acupuncture; Assigned to Arm(s): Minimal Acupuncture, Placebo Acupuncture, Traditional Acupuncture
D: Arm Label: stress management, acupressure; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: pressure pain sensitivity measure followed bu acupressure | Arm Label: bio feedback guided, stress management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: pressure pain sensitivity measure followed bu acupressure; Assigned to Arm(s): stress management, acupressure

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bronchoscopy Under Titrated Sedation With Propofol or Midazolam: a Randomized Trial.
Brief Summary: Bronchoscopy is performed on a daily basis for diagnostic and therapeutic purposes. This procedure may cause anxiety and discomfort requiring the use of sedative drugs.

In this study the investigators titrate the administration of sedatives using bispectral analysis of the EEG. The investigators compared 2 drugs, propofol versus midazolam regarding patient subjective tolerance, recovery of brain function, safety and operator's satisfaction.


Options:
A: Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): Propofol | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam
B: N/A
C: Arm Label: anesthesia monitoring; Type: EXPERIMENTAL; Interventions: Device: bispectral index monitoring | Arm Label: no bispectral index monitoring; Type: EXPERIMENTAL; Interventions: Device: bispectral index monitoring | Intervention Type: DEVICE; Name: bispectral index monitoring; Assigned to Arm(s): anesthesia monitoring, no bispectral index monitoring
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Closed-loop system | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: TCI (Infusion Toolbox) | Intervention Type: DEVICE; Name: Closed-loop system; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: TCI (Infusion Toolbox); Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Randomised, Placebo-controlled Study Comparing the Efficacy and Safety of Two Fixed Dosages of a Novel Antidepressant Compound to That of Placebo in Patients With Major Depressive Disorder
Brief Summary: The purpose of this Venlafaxine-referenced study is to evaluate the efficacy, safety and tolerability of two fixed doses of Vortioxetine in the acute treatment of Major Depressive Disorder (MDD).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Duloxetine 60 mg; Type: OTHER; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine 5 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine 60 mg
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine (Lu AA21004) 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Vortioxetine (Lu AA21004) 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Venlafaxine XL 225 mg; Type: OTHER; Interventions: Drug: Venlafaxine XL | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine (Lu AA21004) 10 mg, Vortioxetine (Lu AA21004) 5 mg | Intervention Type: DRUG; Name: Venlafaxine XL; Assigned to Arm(s): Venlafaxine XL 225 mg
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Vortioxetine 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine 10 mg | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine 20 mg
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Vortioxetine 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Intervention Type: DRUG; Name: Vortioxetine; Assigned to Arm(s): Vortioxetine 10 mg, Vortioxetine 20 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study (EVAS): Effect of Eicosapentaenoic Acid on Cerebral Vasospasm Following Subarachnoid Hemorrhage
Brief Summary: Cerebral vasospasm following subarachnoid hemorrhage (SAH) is the most common cause of morbidity and mortality. Recent studies indicate that Rho-kinase play an important role in the occurrence of such cerebral vasospasm. Eicosapentaenoic acid (EPA) inhibits sphingosylphosphorylcholine (SPC)-induced Rho-kinase activation in vitro. So this study examines whether EPA prevents cerebral vasospasm occurrence after SAH in patients.


Options:
A: Intervention Type: BEHAVIORAL; Name: Dietary intake; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle factors; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Blood biomarkers; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Health; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: DNA; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Mental well-being; Assigned to Arm(s): N/A
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Eicosapentaenoic acid ethyl ester | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester; Assigned to Arm(s): A
C: Arm Label: AMR101; Type: EXPERIMENTAL; Interventions: Drug: AMR101, Drug: Statin therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Statin therapy | Intervention Type: DRUG; Name: AMR101; Assigned to Arm(s): AMR101 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): AMR101, Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study (EVAS): Effect of Eicosapentaenoic Acid on Cerebral Vasospasm Following Subarachnoid Hemorrhage
Brief Summary: Cerebral vasospasm following subarachnoid hemorrhage (SAH) is the most common cause of morbidity and mortality. Recent studies indicate that Rho-kinase play an important role in the occurrence of such cerebral vasospasm. Eicosapentaenoic acid (EPA) inhibits sphingosylphosphorylcholine (SPC)-induced Rho-kinase activation in vitro. So this study examines whether EPA prevents cerebral vasospasm occurrence after SAH in patients.


Options:
A: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: AMR101 (ethyl icosapentate) - 2 g/day; Type: EXPERIMENTAL; Interventions: Drug: AMR101 (ethyl icosapentate) - 2 g/day | Arm Label: AMR101 (ethyl icosapentate) - 4 g/day; Type: EXPERIMENTAL; Interventions: Drug: AMR101 (ethyl icosapentate) - 4 g/day | Intervention Type: DRUG; Name: AMR101 (ethyl icosapentate) - 4 g/day; Assigned to Arm(s): AMR101 (ethyl icosapentate) - 4 g/day | Intervention Type: DRUG; Name: AMR101 (ethyl icosapentate) - 2 g/day; Assigned to Arm(s): AMR101 (ethyl icosapentate) - 2 g/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Eicosapentaenoic acid ethyl ester | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester; Assigned to Arm(s): A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Symbicort® SMART (160/4.5μg) and Symbicort® Turbuhaler 160/4.5 μg, Plus Terbutaline Turbuhaler 0.4 mg as Needed, for Treatment of Asthma - a 12-month, Randomized, Double-blind, Parallel Group, Active-controlled, Multinational Phase III Study in Asthmatic Patients From 16 Years
Brief Summary: The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg as needed, as asthma therapy


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Symbicort (Budesonide/Formoterol) | Intervention Type: DRUG; Name: Symbicort (Budesonide/Formoterol); Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Symbicort Turbuhaler | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort Turbuhaler, Drug: Terbutaline Turbuhaler | Intervention Type: DRUG; Name: Symbicort Turbuhaler; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Terbutaline Turbuhaler; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: salbutamol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol | Intervention Type: DRUG; Name: salbutamol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol (Advair) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: fluticasone/salmeterol (Advair); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy
Brief Summary: The purpose of this study is to assess whether adherence to NVUGIB guidelines is improved with implementation of a national, tailored multifaceted intervention. Outcomes include adherence rates to two key endoscopic and pharmacological therapy guidelines together (primary), or adherence to these individually as well as to other recommendations (secondary). Patient outcomes and economic data are also assessed (tertiary).


Options:
A: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention
B: Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: screening colonoscopy; Assigned to Arm(s): N/A
C: Arm Label: physician chart reminder; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physician chart reminder | Arm Label: chart reminder, educational mat'ls, FIT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physician chart reminder, Behavioral: chart reminder, educational mat'ls, FIT | Arm Label: CR, ed mat'ls, FIT, phone call; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physician chart reminder, Behavioral: CR,ed mat'ls, FIT, phone call | Intervention Type: BEHAVIORAL; Name: Physician chart reminder; Assigned to Arm(s): CR, ed mat'ls, FIT, phone call, chart reminder, educational mat'ls, FIT, physician chart reminder | Intervention Type: BEHAVIORAL; Name: chart reminder, educational mat'ls, FIT; Assigned to Arm(s): chart reminder, educational mat'ls, FIT | Intervention Type: BEHAVIORAL; Name: CR,ed mat'ls, FIT, phone call; Assigned to Arm(s): CR, ed mat'ls, FIT, phone call
D: Intervention Type: BEHAVIORAL; Name: Disease Management Assessment; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy
Brief Summary: The purpose of this study is to assess whether adherence to NVUGIB guidelines is improved with implementation of a national, tailored multifaceted intervention. Outcomes include adherence rates to two key endoscopic and pharmacological therapy guidelines together (primary), or adherence to these individually as well as to other recommendations (secondary). Patient outcomes and economic data are also assessed (tertiary).


Options:
A: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Fall Prevention Tool Kit prototype using a randomized design | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Fall Prevention Tool Kit prototype using a randomized design; Assigned to Arm(s): 1
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: automated clinical alerts, Other: provider education | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: provider education | Intervention Type: OTHER; Name: automated clinical alerts; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: provider education; Assigned to Arm(s): 1, 2
D: Arm Label: Clinical Reminder; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical Reminder | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Clinical Reminder; Assigned to Arm(s): Clinical Reminder

Answer: A